We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.88 | 1.19% | 1,094.99 | 1,094.36 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 22:39:15 |
|
New York
|
| |
13-3444607
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization) |
| |
(I.R.S. Employer
Identification No.) |
|
|
Large accelerated filer
☒
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☐
|
| |
Smaller reporting company
☐
Emerging growth company
☐
|
|
| | |
Page
|
| |||
| | | | ii | | | |
| | | | iii | | | |
| | | | iv | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | |
|
Securities and Exchange Commission Registration Fee
|
| | | $ | * | | |
|
Accounting Fees and Expenses
|
| | | $ | ** | | |
|
Legal Fees and Expenses
|
| | | $ | ** | | |
|
Printing Fees
|
| | | $ | ** | | |
|
Transfer Agent and Trustees’ Fees and Expenses
|
| | | $ | ** | | |
|
Rating Agency Fees
|
| | | $ | ** | | |
|
Stock Exchange Listing Fees
|
| | | $ | ** | | |
|
Miscellaneous
|
| | | $ | ** | | |
|
Total
|
| | | $ | ** | | |
| 1.1* | | | Form of Underwriting Agreement. | |
| 4.1 | | | Restated Certificate of Incorporation of Regeneron Pharmaceuticals, Inc., as amended (incorporated by reference to Exhibit 3.1 to the Form 10-Q for Regeneron Pharmaceuticals, Inc. for the quarter ended June 30, 2015, filed on August 4, 2015). | |
| 4.2 | | | | |
| 4.3 | | | | |
| 4.4* | | | Specimen Preferred Stock Certificate and Form of Certificate of Designation, Preferences, and Rights with respect to any series of Preferred Stock issued hereunder. | |
| 4.5 | | | Indenture, dated August 12, 2020, between Regeneron Pharmaceuticals, Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Form 8-K for Regeneron Pharmaceuticals, Inc., filed on August 12, 2020). | |
| 4.6* | | | Form of any Debt Security. | |
| 4.7* | | | Form of Warrant Agreement (including form of Warrant Certificate). | |
| 5.1 | | | | |
| 23.1 | | | | |
| 23.2 | | | | |
| 24.1 | | | | |
| 25.1 | | | |
| | | | REGENERON PHARMACEUTICALS, INC. | | |||
| | | | By: | | |
/s/ Robert E. Landry
Name: Robert E. Landry
Title:
Executive Vice President, Finance and Chief Financial Officer
|
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ LEONARD S. SCHLEIFER
Leonard S. Schleifer, M.D., Ph.D.
|
| |
President, Chief Executive Officer,
and Director (Principal Executive Officer) |
| |
November 4, 2021
|
|
|
/s/ ROBERT E. LANDRY
Robert E. Landry
|
| |
Executive Vice President, Finance and
Chief Financial Officer (Principal Financial Officer) |
| |
November 4, 2021
|
|
|
/s/ CHRISTOPHER R. FENIMORE
Christopher R. Fenimore
|
| |
Senior Vice President, Controller
(Principal Accounting Officer) |
| |
November 4, 2021
|
|
|
/s/ GEORGE D. YANCOPOULOS
George D. Yancopoulos, M.D., Ph.D.
|
| |
President, Chief Scientific Officer, and
Director |
| |
November 4, 2021
|
|
|
/s/ P. ROY VAGELOS
P. Roy Vagelos, M.D.
|
| |
Chairman of the Board
|
| |
November 4, 2021
|
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ BONNIE L. BASSLER
Bonnie L. Bassler, Ph.D.
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ MICHAEL S. BROWN
Michael S. Brown, M.D.
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ N. ANTHONY COLES
N. Anthony Coles, M.D.
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ JOSEPH L. GOLDSTEIN
Joseph L. Goldstein, M.D.
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ CHRISTINE A. POON
Christine A. Poon
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ ARTHUR F. RYAN
Arthur F. Ryan
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ GEORGE L. SING
George L. Sing
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ MARC TESSIER-LAVIGNE
Marc Tessier-Lavigne, Ph.D.
|
| |
Director
|
| |
November 4, 2021
|
|
|
/s/ HUDA Y. ZOGHBI
Huda Y. Zoghbi, M.D.
|
| |
Director
|
| |
November 4, 2021
|
|
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions